Cargando…

A Study on the Correlation Between MDR1 Polymorphism and Clopidogrel Resistance in Hui Patients Treated with Percutaneous Coronary Intervention

OBJECTIVE: This study assesses the correlation between MDR1 gene polymorphism and clopidogrel resistance (CR) in Hui patients with coronary heart disease (CHD) who were treated with percutaneous coronary intervention (PCI). METHODS: The study includes 204 Ningxia Hui patients with CHD who were treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Fang, Zhang, Jing, Bian, Cheng-Xue, Zhang, Jian, Xin, Xiang-Bin, Pan, Yang-Yang, Zhang, Xuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920608/ https://www.ncbi.nlm.nih.gov/pubmed/33658839 http://dx.doi.org/10.2147/IJGM.S293947

Ejemplares similares

The Correlation Between MDR1 Gene Polymorphism and Clopidogrel Resistance in People of the Hui and Han Nationalities
por: Zhang, Jing, et al.
Publicado: (2022)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
por: YANG, Bin, et al.
Publicado: (2018)

Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes
por: Dong, Peng, et al.
Publicado: (2016)

Association of ABCC2 polymorphism with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention
por: Chen, Lida, et al.
Publicado: (2022)

Association of ABCB1 Gene Polymorphisms and Clopidogrel Responsiveness in Iranian Patients undergoing Percutaneous Coronary Intervention
por: Namazi, Soha, et al.
Publicado: (2020)

The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention
por: Zhang, Zhaowei, et al.
Publicado: (2020)

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Xi, Ziwei, et al.
Publicado: (2021)

Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention
por: Dasgupta, Arijit, et al.
Publicado: (2009)

Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis
por: Pang, Jun, et al.
Publicado: (2019)

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Li, Jianan, et al.
Publicado: (2021)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Aspirin in combination with clopidogrel in the treatment of acute myocardial infarction patients undergoing percutaneous coronary intervention
por: Zhang, Xiaoyan, et al.
Publicado: (2019)

Associations of PER3 polymorphisms with clopidogrel resistance among Chinese Han people treated with clopidogrel
por: Zheng, Nan, et al.
Publicado: (2021)

Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
por: Zheng, Wei, et al.
Publicado: (2019)

Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis
por: Wang, Dong, et al.
Publicado: (2018)

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
por: Shawky, Ahmed, et al.
Publicado: (2023)

Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry
por: Zhang, Yunnan, et al.
Publicado: (2022)

The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention
por: Haji Aghajani, Mohammad, et al.
Publicado: (2018)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
por: Fan, Zhong-Guo, et al.
Publicado: (2019)

High-Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
por: Chen, Yu, et al.
Publicado: (2013)

Comparative study of ticagrelor and clopidogrel in therapeutic effect of acute myocardial infarction patients undergoing percutaneous coronary intervention
por: Yao, Guangtao, et al.
Publicado: (2017)

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
por: Mugosa, Snezana, et al.
Publicado: (2021)

Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention
por: Jeong, Young-Hoon, et al.
Publicado: (2012)

Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
por: Chen, Shuxia, et al.
Publicado: (2017)

Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention
por: Lee, Dongyoung, et al.
Publicado: (2021)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

Association of KDR rs1870377 genotype with clopidogrel resistance in patients with post percutaneous coronary intervention
por: Al Awaida, Wajdy, et al.
Publicado: (2021)

Genetic Origins and Sex-Biased Admixture of the Huis
por: Ma, Xixian, et al.
Publicado: (2021)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007–2017)
por: Guan, Wenjun, et al.
Publicado: (2018)

Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy
por: Liu, Ping-Yen, et al.
Publicado: (2021)

Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China
por: Li, Jiawen, et al.
Publicado: (2021)

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Wang, He-Yang, et al.
Publicado: (2018)

Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
por: Kwan, Joanne, et al.
Publicado: (2011)

Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban
por: Campo, Gianluca, et al.
Publicado: (2010)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
por: Maret-Ouda, John, et al.
Publicado: (2021)

Design aujourd'hui /
por: Colin, Christine, 1952-
Publicado: (1988)

QnAs with Hui Cao
por: Ahmed, Farooq
Publicado: (2022)

The Impact of Kinase Insert Domain (KDR) Gene Polymorphism rs2305948 on Clopidogrel Resistance in Iraqi Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)
por: Ahmed, Ali A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fqiucom0ujrrmo4le38tjgs74c